Alzheimer's disease is incurable but preventable

Journal of Alzheimer's Disease

Volumn 20, Issue 3, 2010, Pages 861-870

  De La Torre, Jack C ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Alzheimer's risk factors; cognition; evidence based medicine; neurodegeneration; prevention; ultrasound screen

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SATURATED FATTY ACID;

AGING; ALCOHOLISM; ALZHEIMER DISEASE; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; BLOOD CLOTTING; BLOOD FLOW VELOCITY; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ARTERY ULTRASOUND; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ECHOGRAPHY; EDUCATIONAL STATUS; EVIDENCE BASED MEDICINE; FORWARD HEART FAILURE; HEAD INJURY; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART OUTPUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; MASS SCREENING; MENOPAUSE; MENTAL DETERIORATION; MIGRAINE; MITRAL VALVE REGURGITATION; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NUTRITIONAL DEFICIENCY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; TRICUSPID VALVE REGURGITATION; TUMOR GROWTH; VALVULAR HEART DISEASE;

EID: 77954553168     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091579     Document Type: Review

References (54)

1. Alzheimer's Association (2009) Alzheimer's disease facts and figures. Alzheimers Dement 5, 234-270.
2. Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y (2006) Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology 66, 1021-1028.
3. de la Torre JC (1996) Omental transposition for Alzheimer's disease. Neurol Res 18, 295-296.
4. Schneider LS, Sano M (2009) Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 5, 388-397.
5. Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A (2003) Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev, CD003260.
6. Aisen PS (2009) Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther 1, 2.
7. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223.
8. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR Jr (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63, 204-212.
9. Giannakopoulos P, Herrmann FR, Bussìere T, Bouras C, K̈ovari E, PerlDP, Morrison JH, Gold G, HofPR(2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500.
10. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Ngren K, Kim BC, TsuiW, de Leon MJ (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35, 2169-2181.
11. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA (2009) Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18, 447-1152
12. Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007) Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321, 823-829.
13. Smith MA, Atwood CS, Joseph JA, Perry G (2002) Predicting the failure of amyloid-beta vaccine. Lancet 359, 1864-1865.
14. Selkoe D (1994) Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr Opin Neurobiol 4, 708-716.
15. Olanow CW, Kordower JH, Freeman TB (1996) Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19, 102-109.
16. Northoff G (1996) Do brain tissue transplants alter personal identity? Inadequacies of some "standard" arguments. J Med Ethics 22, 174-180.
17. Bokde AL, Ewers M, Hampel H (2009) Assessing neuronal networks: understanding Alzheimer's disease. Prog Neurobiol 89, 125-133.
18. Clarfield AM (1988) The reversible dementias: do they reverse? Ann Intern Med 109, 476-486.
19. Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43, 2412-2414.
20. Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16, 4491-4500.
21. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259.
22. Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H (1999) Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 249 Suppl 3, 14-22.
23. Haaw JJ, Duyckaerts C (2001) Alzheimer's disease. In: Pathology of the Aging Human Nervous System, 2nd Ed. Duckett S, de la Torre JC, eds., Oxford University Press, pp. 207- 263.
24. Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11, 111-128.
25. Breteler MM(2000) Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21, 153-160.
26. van Duijn CM, Hofman A (1992) Risk factors for Alzheimer's disease: the EURODEM collaborative re-analysis of casecontrol studies. Neuroepidemiology 11 Suppl 1, 106-113.
27. Kivipelto M, Helkala EL, Laakso M, Ḧanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322, 1447-1451.
28. Piguet O, Grayson D, Creasey H, Bennet H, Brooks W,Waite L, Broe G(2003) Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology 22, 165-171.
29. Wynder EL, Graham EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: a study of six hundred and eighty-four proved cases. JAMA 143, 329-336.
30. Ries LAG, Eisner MP, Kosary CL, et al. (eds). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD, 2004. lung cancer 87% due to smoking.
31. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society, 2004.
32. de la Torre JC (2004) Is Alzheimer's a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol 3, 184-190.
33. de la Torre JC (2006) How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 28, 637-644.
34. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, JagustW, Ives D, Dekosky ST, Kuller LH (2005) Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 53, 1101-1107.
35. Murad MH, Montori VM (2010) Evidence based medicine: application in Alzheimer's disease research. J Alzheimers Dis, in press.
36. Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, Moyer V (2004) Relative risk reduction, absolute risk reduction and number needed to treat. Can Med Assoc J 171, 353-358.
37. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW,Westendorp RG (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 257, 85-90.
38. Sztriha LK, Nemeth D, Sefcsik T, Vecsei L (2009) Carotid stenosis and the cognitive function. J Neurol Sci 283, 36-40.
39. McGuinness B, Todd S, Passmore P, Bullock R (2006) The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev, CD004034.
40. Malouf R, Grimley-Evans J (2008) Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev, CD004514.
41. Lloret A, Bad́?a MC, Mora NJ, Pallard́o FV, Alonso MD, Vĩna J (2009) Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17, 143-149.
42. Middleton LE, Yaffe K (2009) Promising strategies for the prevention of dementia. Arch Neurol 66, 1210-1215.
43. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331, 321-327.
44. Dyer C (2009) NICE reiterates that people with mild Alzheimer's disease should not get drug treatment. BMJ 338, b2413.
45. de la Torre JC (2008) Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 5, 126-132.
46. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
47. de la Torre JC (2008) Alzheimer's disease prevalence can be lowered with non-invasive testing. J Alzheimers Dis 14, 353-359.
48. de la Torre JC (2009) Carotid artery ultrasound and echocardiography (CAUSE) testing to lower the prevalence of Alzheimer's disease. J Stroke Cerebrovasc Dis 18, 319-328.
49. de la Torre JC (2000) Critically attained threshold of cerebral hypoperfusion (CATCH): Can it cause Alzheimer's disease? Ann NY Acad Sci 903, 424-436.
50. de la Torre JC (2010) The vascular hypothesis of Alzheimer's disease: Bench to bedside and beyond. Neurodegener Dis 7, 116-121.
51. Kitagawa K, Oku N, Kimura Y, Yagita Y, Sakaguchi M, Hatazawa J, Sakoda S (2009) Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. Hypertens Res 32, 816-820.
52. DeschaintreY, Richard F, Leys D, Pasquier F (2009)Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73, 674-680.
53. Angell M (2004) The Truth About the Drug Companies. Random House Inc., New York.
54. Laupacis A, Sackett DL, Roberts R (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318, 1728-1733.